CN116570703A - 一种解酒护肝的茶黄素组合物及其制备方法 - Google Patents
一种解酒护肝的茶黄素组合物及其制备方法 Download PDFInfo
- Publication number
- CN116570703A CN116570703A CN202310859488.2A CN202310859488A CN116570703A CN 116570703 A CN116570703 A CN 116570703A CN 202310859488 A CN202310859488 A CN 202310859488A CN 116570703 A CN116570703 A CN 116570703A
- Authority
- CN
- China
- Prior art keywords
- theaflavin
- parts
- alcohol
- extract
- protecting liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014620 theaflavin Nutrition 0.000 title claims abstract description 69
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 title claims abstract description 67
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 229940026509 theaflavin Drugs 0.000 title claims abstract description 67
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 title claims abstract description 65
- 230000000694 effects Effects 0.000 title claims abstract description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 210000004185 liver Anatomy 0.000 title claims abstract description 45
- 230000002633 protecting effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 24
- 230000005496 eutectics Effects 0.000 claims abstract description 24
- 229920001184 polypeptide Polymers 0.000 claims abstract description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 24
- 239000002904 solvent Substances 0.000 claims abstract description 24
- 235000020234 walnut Nutrition 0.000 claims abstract description 24
- 229920002752 Konjac Polymers 0.000 claims abstract description 22
- 244000197580 Poria cocos Species 0.000 claims abstract description 22
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 22
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 22
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 22
- 235000010485 konjac Nutrition 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 18
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 239000000706 filtrate Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 10
- 238000002137 ultrasound extraction Methods 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 238000000227 grinding Methods 0.000 claims abstract description 6
- 238000007873 sieving Methods 0.000 claims abstract description 6
- 238000000967 suction filtration Methods 0.000 claims abstract description 6
- 238000007796 conventional method Methods 0.000 claims abstract description 3
- 240000007049 Juglans regia Species 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims description 25
- 206010019133 Hangover Diseases 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 12
- 230000004224 protection Effects 0.000 claims description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 6
- PNLQPWWBHXMFCA-UHFFFAOYSA-N 2-chloroprop-1-ene Chemical compound CC(Cl)=C PNLQPWWBHXMFCA-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002608 ionic liquid Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 30
- 241000758789 Juglans Species 0.000 description 19
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 14
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 241000411851 herbal medicine Species 0.000 description 13
- 230000035622 drinking Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000001603 reducing effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 6
- 235000014101 wine Nutrition 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000002075 anti-alcohol Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000013616 tea Nutrition 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010001605 Alcohol poisoning Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 description 3
- KMJPKUVSXFVQGZ-UHFFFAOYSA-N TF2B Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- -1 theaflavin compound Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZEASWHWETFMWCV-ISBUVJFSSA-N Theaflavin 3,3'-digallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C2=CC(=CC(=O)C(O)=C2C(O)=C(O)C=1)[C@@H]1[C@@H](CC2=C(O)C=C(O)C=C2O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-ISBUVJFSSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- AATSUYYYTHJRJO-UHFFFAOYSA-N theaflavin 3-gallate Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC(=O)C(O)=C1C(O)=C2O)C=C1C=C2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-UHFFFAOYSA-N 0.000 description 2
- 235000007900 theaflavin-3-gallate Nutrition 0.000 description 2
- AATSUYYYTHJRJO-RZYARBFNSA-N theaflavin-3-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=C(O)C(O)=C2C(=O)C(O)=CC(=CC2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 AATSUYYYTHJRJO-RZYARBFNSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002707 Digallic acid Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- BVMDSEFJGKQBKJ-UHFFFAOYSA-N Theaflavin 3'-gallate Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O BVMDSEFJGKQBKJ-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- IKLDTEFDTLKDRK-UHFFFAOYSA-N theaflavin 3'-gallate Natural products OC1Cc2c(O)cc(O)cc2OC1c3cc4C=C(C=C(O)C(=O)c4c(O)c3O)C5Oc6cc(O)cc(O)c6CC5OC(=O)c7cc(O)c(O)c(O)c7 IKLDTEFDTLKDRK-UHFFFAOYSA-N 0.000 description 1
- 235000002365 theaflavin-3'-gallate Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种解酒护肝的茶黄素组合物及其制备方法,属于保健品技术领域,所述茶黄素组合物主要由茶黄素、魔芋、核桃多肽、赤小豆、茯苓和桂枝制成;茶黄素组合物的制备方法包括以下步骤:步骤S1、将魔芋、桂枝、茯苓和赤小豆磨成细粉,过筛,加入低共熔溶剂,在微波和光波组合下超声提取,抽滤,重提,合并滤液,得到提取液,旋蒸得到提取物;步骤S2、将提取物、核桃多肽、茶黄素和水混合,煎煮,合并煎煮液,过滤,将滤液减压浓缩,得浸膏,将浸膏与常规辅料混合,按常规方法制备得到解酒护肝的茶黄素组合物;本发明提供的茶黄素组合物制成的口服制剂,有着良好的解酒护肝功效,此外,低共熔溶剂易制备和除去,安全环保。
Description
技术领域
本发明属于保健品技术领域,具体地,涉及一种解酒护肝的茶黄素组合物及其制备方法。
背景技术
茶黄素类化合物是红茶加工过程中形成的具有苯骈卓酚酮结构的高活性复合物,由于其在降血压、降血糖和抗氧化等方面均具有良好的活性,因此,被广泛应用于保健品和医药等领域。
但是由于茶黄素易被氧化,现有技术中很难提取到高含量的茶黄素,同时,其在解酒护肝方面的功效过于单一,无法满足实际生活的需求。
为了克服上述问题,本申请以茶黄素为主料,通过多种活性成份的复配使用,以期得到疗效显著的解酒护肝的茶黄素组合物。
发明内容
本发明的目的在于提供以解决以下技术问题:
如何制备得到一种疗效显著的解酒护肝的茶黄素组合物,使用该茶黄素组合物配成的口服制剂,用法用量操作简单,同时提取溶剂环保,易被去除。
本发明的目的可以通过以下技术方案实现:
一种解酒护肝的茶黄素组合物,主要按照质量份数的以下原料制成:
180-220份茶黄素、70-80份魔芋、90-110份核桃多肽、40-60份赤小豆、40-60份茯苓和40-60份桂枝;
在本发明的解酒护肝的茶黄素组合物的一个示例性实施例中,解酒护肝的茶黄素组合物原料包括按质量份数计的以下成分:茶黄素190-210份、魔芋72-76份、核桃多肽95-105份、赤小豆45-55份、茯苓45-55份和桂枝40-60份;进一步地,可包括:茶黄素200份、魔芋74份、核桃多肽100份、赤小豆50份、茯苓50份和桂枝50份。
本发明另一方面提供了一种解酒护肝的茶黄素组合物的制备方法。
在本发明的解酒护肝的茶黄素组合物的制备方法的一个或多个示例性实施例中,解酒护肝的茶黄素组合物的制备方法包括以下步骤:
步骤S1、将魔芋、桂枝、茯苓和赤小豆磨成细粉,过100目筛,加入4倍重量低共熔溶剂搅拌均匀,继续浸泡2-3h,微波和光波组合下超声提取,抽滤,取残渣再提取1次,合并滤液,得到提取液,旋蒸除去低共熔溶剂,得到提取物;
步骤S2、将提取物、核桃多肽、茶黄素和水混合,煎煮若干次,合并煎煮液,过滤,将滤液减压浓缩,得浸膏,将浸膏与常规辅料混合,按照常规方法制备得到解酒护肝的茶黄素组合物。
进一步地,微波和光波下超声提取为在微波炉中55%微波和45%光波组合、辐射功率为800W的条件下超声提取4-10min。
在本发明的解酒护肝的茶黄素组合物的制备方法的一个或多个示例性实施例中,煎煮的次数可为三次,第一次加入所述中草药类原料总质量6-10倍的水煎煮2-4h,第二次加入所述中草药类原料总质量3-5倍的水煎煮1-2h,第三次加入所述中草药类原料总质量2-4倍的水煎煮0.5-1h。
在本发明的解酒护肝的茶黄素组合物的制备方法的一个或多个示例性实施例中,低共熔溶剂的制备方法,包括以下步骤:
步骤A1、将N-甲基咪唑加入2-氯丙烯中,机械搅拌均匀,N2的保护下,升温至55-65℃,搅拌反应6-8h,反应结束后,与无水***混合,搅拌均匀,静置2-4h,分液,再对离子液体进行旋转蒸发,在80℃真空干燥48h,得到1-甲基-3-烯丙基咪唑盐酸盐,其中,N-甲基咪唑、2-氯丙烯和无水***的用量比为20-26mL:24-30mL;10-20mL,1-甲基-3-烯丙基咪唑盐酸盐的结构简式如下所示:
步骤A2、将1-甲基-3-烯丙基咪唑盐酸盐和尿素加入三口烧瓶中,氮气保护下,升温至90℃,搅拌反应2-3h,得到低共熔溶剂,其中,1-甲基-3-烯丙基咪唑盐酸盐和尿素的用量比为15-25g:7.5-12.5g,在上述反应过程中,以尿素为氢键供体,1-甲基-3-烯丙基咪唑盐酸盐为氢键受体,通过反应得到有绿色、经济和环境友好且具有良好的生物可降解性的低共熔溶剂。
本发明的有益效果:
(1)本发明以核桃多肽以及茶黄素为主要功效成分,来减低酒精肝损伤,并通过中草药复方来提高解酒护肝功效;其中魔芋味辛性凉,辛能解表发汗、化湿醒脾,凉能清热,散酒浊,清郁热,有“解酒醒脾”之效,而添加的赤小豆及魔芋均有护肝的作用,桂枝性温可以达温寒互制,使得药性平和,醒脑开窍,同时本发明中茯苓治眩晕头痛、改善症状,愉快心情,使药物发挥更大功能。
(2)本发明中的主要成分为核桃多肽和茶黄素,研究发现,前者可以增加小鼠肝脏中ADH 酶的活性,加速乙醇的代谢,通过促进脾胃的运化,肝的疏泄充,养髓海从而起到解酒护肝的作用,后者能干预引起慢性酒精中毒大鼠内脏脂肪中释放的脂肪酸减少,从白色脂肪组织—肝脏轴角度减少了流向肝脏的脂肪酸,减少了肝细胞对脂肪酸的摄取,进而减少了脂质在肝脏的堆积,缓解肝脏的氧化应激,降低了血清中总胆固醇、甘油三酯和低密度脂蛋白胆固醇的含量,减轻肝脏损伤,核桃多肽、茯苓中的茯苓多糖和赤小豆中的黄酮类活性成分均具有良好的抗氧化作用,同时,通过三者的相互协同作用,抑制酒精造成的氧化应激、肝细胞凋亡,脂质蓄积进而实现更好的护肝作用。
(3)相较于传统的有机溶剂提取方法,本发明中采用的微波和光波下超声提取的具有适用范围广,提取效率高,重现性好,省时间,节省试剂,污染小等特点,同时,制备得到的低共熔溶剂中含有高浓度的氯离子和阳离子活性成分与魔芋中的魔芋葡甘聚糖、桂枝中的桂皮油、桂皮酯和桂皮醛等活性成分、茯苓中的茯苓多糖和赤小豆中黄酮类活性成分均具有良好的氢键作用,对上述物质的活性成分有着极佳的溶解性,同时,通过上述步骤制备得到的低共熔溶剂的沸点相对较低,通过旋蒸法很容易去除。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
以下为各原料的药理功效:
核桃多肽:具有抗炎、抗氧化、健脑、保护胃黏膜、降血脂血糖等生物活性,还在不同记忆损伤动物模型中显现出明显的神经保护作用调节胆碱能的功能障碍等,有效改善由酒精导致的认知和情绪损伤。研究已经表明核桃多肽对酒精肝脏损伤具有一定的缓解作用,有研究表明,乙醇喂养的大鼠血液中的丙氨酸转氨酶和天冬氨酸转氨酶的含量显著下降,而核桃多肽喂养的大鼠这两个转氨酶的水平都有所提高,说明核桃多肽对减轻酒精性肝病有疗效。
茶黄素在茶叶的加工过程中,多酚类物质经过氧化缩合而形成的一类具有苯并卓酚酮结构、能溶于乙酸乙酯的化合物的总称,共有12种组分,其中茶黄素(TF)、茶黄素-3-没食子酸酯(TF-3-G)、茶黄素-3,3’-双没食子酸酯(TFDG)和茶黄素-3’-没食子酸酯(TF-3’-G)是4种最主要的茶黄素。现代药理学活性研究表明,茶黄素能有效抑制小鼠体重的增加和脂肪细胞的形成,降低血清中TC、 TG和LDL-C的含量,减轻对肝组织的损伤。
魔芋:寒,味辛、苦,有着清热利湿、行气消瘀、软坚散结的功效,研究表明,魔芋的主要化学成分为魔芋葡甘聚糖,其具有良好的的抗疲劳作用和降血糖、改善糖耐量作用,同时,在针对小鼠的研究中发现,其能使血液中乙醇含量降低,有较好的解酒效果。
赤小豆:平,苦。归脾、肝经。可以用于理气活血;清热解毒,其含有较多的膳食纤维,能解酒、解毒,对心脏病、肾病和水肿均有一定疗效,赤小豆在本发明中作为辅药,具有良好的降血压、调血脂血糖和良好的利尿作用。
桂枝:辛、甘,温,归心、肺、膀胱经。具有发汗解表,温经通阳的功能。近年来,经临床观察发现,其对消化***具有抗溃疡、双向调节肠运动和保肝利胆作用,对子宫平滑肌和支气管具有双向调节作用,对心血管***具有降低血压,溶栓、增加血流量、扩张血管等作用。其性辛,甘,温,归心、肺、膀胱经。具有发汗解表,温经通阳的功能,用于治疗肝胃虚寒、阴浊上逆所致的头痛或胃脘疼痛等症状。
茯苓:性平,味淡、甘,归心、脾、肺、肾经,具有利水渗湿、宁心、健脾的功效,可用于治疗水肿尿少、脾虚食少、痰饮眩悸、便溏泄泻、惊悸失眠、心神不安等病症,茯苓中含有大量的茯苓多糖,现代研究表明,茯苓多糖不仅可以通过调节肝脂肪变性小鼠的肠道微生物群有效改善肝脏炎症损伤及脂肪堆积,而且可通过抑制细胞死亡和减少肝炎性应激等途径来修复体内对乙酰氨基酚诱导的肝损伤,起到保肝护肝的作用。
实施例1:
优选地,本实施例提供一种低共熔溶剂的制备方法,包括以下步骤:
步骤A1、将23mL N-甲基咪唑加入27mL 2-氯丙烯中,机械搅拌均匀,N2的保护下,升温至60℃,搅拌反应7h,反应结束后,与无水***混合,搅拌均匀,静置2-4h,分液,再对离子液体进行旋转蒸发,在80℃真空干燥48h,得到1-甲基-3-烯丙基咪唑盐酸盐;
步骤A2、将20g 1-甲基-3-烯丙基咪唑盐酸盐和10g尿素加入三口烧瓶中,氮气保护下,升温至90℃,搅拌反应2.5h,得到低共熔溶剂。
实施例2:
根据本发明的解酒护肝的茶黄素组合物的另一个示例性实施例,茶黄素组合物可包括以下重量份原料:茶黄素190份、魔芋72份、核桃多肽95份、赤小豆45份、茯苓45份和桂枝40份;
在本发明的解酒护肝的茶黄素组合物的制备方法的第一个示例性实施例中,被制备为片剂,制备方法具体如下:
步骤S1、按照上述质量份数称取茶黄素组合物,将魔芋、桂枝、茯苓和赤小豆磨成细粉,过100目筛,加入4倍重量低共熔溶剂搅拌均匀,继续浸泡2h,在微波炉中55%微波和45%光波组合、辐射功率为800W的条件下超声提取 4min,抽滤,取残渣再提取1次,合并滤液,得到提取液,旋蒸除去低共熔溶剂,得到提取物;
步骤S2、将提取物、核桃多肽、茶黄素和水混合,煎煮三次,第一次加入所述中草药类原料总质量6倍的水煎煮2h,第二次加入所述中草药类原料总质量3倍的水煎煮1h,第三次加入所述中草药类原料总质量2倍的水煎煮0.5h,合并煎煮液,过滤,将滤液减压浓缩,得黏稠的近膏状液体,并向上述黏稠的近膏状液体中加入包括填充剂、润滑剂在内的辅料,再通过湿法制粒制备为片剂,其中,上述填充剂、润滑剂均可从现有技术中进行选择,服用方法:每次2-3片,每天3次,4天一个疗程。
实施例3:
根据本发明的解酒护肝的茶黄素组合物的另一个示例性实施例,茶黄素组合物可包括以下重量份原料:茶黄素200份、魔芋74份、核桃多肽100份、赤小豆50份、茯苓50份和桂枝50份;
在本发明的解酒护肝的茶黄素组合物的制备方法的第二个示例性实施例中,被制备为汤剂,制备方法具体如下:
步骤S1、按照上述质量份数称取茶黄素组合物,将魔芋、桂枝、茯苓和赤小豆磨成细粉,过100目筛,加入4倍重量低共熔溶剂搅拌均匀,继续浸泡2.5h,在微波炉中55%微波和45%光波组合、辐射功率为800W的条件下超声提取6min,抽滤,取残渣再提取1次,合并滤液,得到提取液,旋蒸除去低共熔溶剂,得到提取物;
步骤S2、将提取物、核桃多肽、茶黄素和水混合,煎煮三次,煎煮的第一次加入所述中草药类原料总质量8倍的水煎煮3h,第二次加入所述中草药类原料总质量4倍的水煎煮1.5h,第三次加入所述中草药类原料总质量3倍的水煎煮0.75h,合并煎煮液,过滤,并将三次煎煮后获得的滤液进行合并,得药液,冷却,得汤剂,每日1剂,水煎,分3次服。
实施例4:
根据本发明的解酒护肝的茶黄素组合物的另一个示例性实施例,茶黄素组合物可包括以下重量份原料:220份茶黄素、80份魔芋、110份核桃多肽、60份赤小豆、60份茯苓和60份桂枝;
在本发明的解酒护肝的茶黄素组合物的制备方法的第三个示例性实施例中,被制备为胶囊剂,制备方法具体如下:
步骤S1、按照上述质量份数称取茶黄素组合物,将魔芋、桂枝、茯苓和赤小豆磨成细粉,过100目筛,加入4倍重量低共熔溶剂搅拌均匀,继续浸泡3h,在微波炉中55%微波和45%光波组合、辐射功率为800W的条件下超声提取10min,抽滤,取残渣再提取1次,合并滤液,得到提取液,旋蒸除去低共熔溶剂,得到提取物;
步骤S2、将提取物、核桃多肽、茶黄素和水混合,煎煮三次,第一次加入所述中草药类原料总质量10倍的水煎煮4h,第二次加入所述中草药类原料总质量5倍的水煎煮2h,第三次加入所述中草药类原料总质量4倍的水煎煮1h,合并煎煮液,过滤,并将三次煎煮后获得的滤液进行合并,得药液,并向上述药液中加入填充基质、助悬剂、润湿剂和包括明胶、增塑剂和去离子水等配制得到的化胶液在内的辅料,再通过压制法制备为胶囊剂,其中,上述填充基质、助悬剂、润湿剂和化胶剂均可从现有技术中进行选择,服用方法:每次2-3片,每天3次,4天一个疗程。
性能检测
实验一:
1仪器与材料
1.1实验动物
健康雄性NIH小鼠,体重为20g±2g。
1.2材料
1.2.1试剂
56度白酒、乙醇脱氢酶(ADH)、海王金樽片剂、ADH试剂盒、ALT试剂盒,分析纯。
1.2.2仪器
气相色谱分析仪,电子天平
2方法
2.1小鼠耐酒精实验
取60只小鼠,随机分成六组,每组10只,雌雄不分。实验前禁食一夜(12h)。
空白组和模型组用生理盐水按0.1mL/10g体重灌服,对照组按海王金樽0.3g/kg体重(用0.2mL生理盐水溶解)灌服;实验低剂量组、实验中剂量组、实验高剂量组分别以该产品按0.05mL/10g体重、0.10mL/10g体重、0.2mL/10g体重灌服;30min后,空白组每只小鼠以0.15mL/10g体重用蒸馏水灌服,其它小鼠均以56度白酒以0.15mL/10g体重灌服,观察小鼠活动,记录小鼠攀附时间、醉酒率、醉酒时间,记录24h内每组小鼠死亡只数。
2.2血清乙醇浓度和酒精性肝、胃损伤实验
取40只雄性NIH小鼠(体重18-22g),实验前禁食12h。再将小鼠随机分成四组。每日上午空白组、模型组单纯灌生理盐水0.2ml/10g体重,对照组按海王金樽0.1g/kg体重(用0.2mL生理盐水溶解)灌服,实验组以解酒护肝口服液0.1mL/10g体重灌服,30min后,模型组、对照组和实验组(中、高、低剂量组,上述实验组以对比例3制备得到的汤剂为例进行论证)小鼠均以56度白酒按0.10mL/10g体重灌服。连续灌服6d,第六天照常灌服半h后,眼眶取血后立即杀死,取出小鼠的肝脏和胃,肝脏去包膜,胃经除去内容物后用预冷的生理盐水反复冲洗直至洗净,并用滤纸吸干称重,按1:10加入预冷后的1.15%氯化钾溶液分别对肝脏、胃匀浆,测定肝组织、胃组织的乙醇脱氢酶(ADH)活性、乙醛脱氢酶(ALD)活性。ADH、ALD活性以每g组织每min产生的摩尔数表示。实验过程死亡小鼠剔除,不做测试。
3.结果
3.1小鼠耐酒精实验结果(见表1)
表1小鼠醉酒情况及死亡率
表1
注:如小鼠翻正反射消失,证明小鼠醉酒,醉酒率指醉酒小鼠的只数与该组小鼠只数之比;醉酒时间指的是醉酒小鼠被灌服白酒到出现翻正反射消失的时间;醒酒时间指的是从翻正反射消失到重新恢复的时间,以平均值±标准差表示。
由表1可见,与模型组相比,对照组、实验组(中、高、低剂量组,上述实验组以对比例3制备得到的汤剂为例进行论证)均能降低醉酒率、推迟小鼠醉酒时间,并能缩短醒酒时间,且与对照组相比,实验组各组在提高小鼠对酒精的耐受能力。
3.2血清乙醇浓度、ADH活性、ALD活性实验结果(见表2)
表2小鼠血清乙醇浓度、ADH活性、ALD活性
由表2可见,实验发现,与空白组相比,模型组小鼠血清乙醇含量明显升高,且乙醇脱氢酶(ADH)和乙醛脱氢酶(ALD)活性明显降低,差异十分显著(P<0.01),造模成功;在灌服该发明提供的解酒护肝的茶黄素组合物后,与模型组相比,小鼠血清浓度平均降低48.3%,乙醇脱氢酶(ADH)活性平均升高54.5%,(P<0.01),乙醛脱氢酶(ALD)活性平均升高49.5%(P<0.01),且从实验结果看,解酒效果好于海王金樽。
实验二
实施例1一中年男性,45岁,一般饮用52度白酒200mL会出现意失模糊、走路摇晃、呕吐等症状,而且第二天醒来后,还经常会有头晕头疼、记忆力变差等问题。某次在饮52度白酒250mL后出现醉酒症状,给予本发明提供的解酒护肝的茶黄素组合物后,在2h后基本解除醉酒状态。以后多次在饮酒前、中、后饮用本发明饮料,皆显示本发明在过量饮酒后能减少醉酒症状,快速醒酒,减少酒后不适。
实验三
一年轻女性,25岁,因工作需要常常需要过量饮酒应酬,酒后常常会有头晕、呕吐症状,且一般需要6-10h才能清醒。她多次在饮酒前30min服用本发明,未出现明显醉酒现象,仅是出现脸红情况,并且在1.5h后脸红情况完全消失。一次饮酒前未服用本发明,出现较严重醉酒现象,酒后2h,服用本发明180mL,3h后就醒酒,第二天即能正常开车上班。
实验三
一酒力较弱的年轻男性,即使少量饮酒后都会出现脸红、心率加快等症状,如饮用红酒超过150mL,就会出现醉酒等状况,且第二天身上酒气还不能完全挥发,精神萎糜。此次他在参加朋友聚会时,在饮酒前10min服用了本发明饮料,当天饮用12.5度葡萄酒500mL,脸红出现时间大大推迟,且脸红,心率加快等酒后常出现的症状不明显,也未出现宿醉情况,第二天头脑清晰、精神状况良好。
实验四
某男性,40岁,因应酬常饮酒,经常喝醉,醉后第二天全身酒气难消,一旦醉后则至少24h无法继续喝酒。某日中午饮用52度白酒300mL,酒后已出现醉酒状态,因晚上还要应酬,中午酒后3h,饮用本发明180mL,晚上继续喝酒52度白酒200mL。酒后醉酒症状不是很明显,只是到了晚上感觉人很累,口干。继续饮用本发明180mL,第二天6点即醒,且身上没有任何酒气,精神状态良好。
4.结论
目前,解酒药的解酒功能是以降低机体血液中的酒清含量以及代谢产物的浓度来评价的。乙醇在机体内代谢,是以两种途径起作用:一是抑制酒清的胃吸收,二是药物作用于肝代谢酶系,加速乙醇代谢和清降代谢产物,减轻对组织细胞的损伤。综上所述,该解酒护肝口服液预先灌胃,可延长小鼠的醉酒时间,缩短醒酒时间,降低小鼠死亡率,且能降低小鼠血清乙醇浓度,恢复肝脏ADH和ALD活性,在制备过程中使用的低共熔溶剂易制备和除去,安全环保,综上,本实验为该发明就用于临床实验提供了有利依据。
在说明书的描述中,参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
以上内容仅仅是对本发明所作的举例和说明,所属本技术领域的技术人员对所描述的具体实施例做各种各样的修改或补充或采用类似的方式替代,只要不偏离发明或者超越本权利要求书所定义的范围,均应属于本发明的保护范围。
Claims (8)
1.一种解酒护肝的茶黄素组合物,其特征在于,所述茶黄素组合物主要按照质量份数的以下原料制成:180-220份茶黄素、70-80份魔芋、90-110份核桃多肽、40-60份赤小豆、40-60份茯苓和40-60份桂枝。
2.根据权利要求1所述的一种解酒护肝的茶黄素组合物,其特征在于,原料包括按质量分数计的以下成分:茶黄素190-210份、魔芋72-76份、核桃多肽95-105份、赤小豆45-55份、茯苓45-55份和桂枝40-60份。
3.一种如权利要求1-2任一项所述的解酒护肝的茶黄素组合物的制备方法,其特征在于,包括以下步骤:
步骤S1、将魔芋、桂枝、茯苓和赤小豆磨成细粉,过100目筛,加入4倍重量低共熔溶剂搅拌均匀,继续浸泡2-3h,微波和光波组合下超声提取,抽滤,取残渣再提取1 次,合并滤液,得到提取液,旋蒸除去低共熔溶剂,得到提取物;
步骤S2、将提取物、核桃多肽、茶黄素和水混合,煎煮若干次,合并煎煮液,过滤,将滤液减压浓缩,得浸膏,将浸膏与常规辅料混合,按照常规方法制备得到解酒护肝的茶黄素组合物;
低共熔溶剂先由N-甲基咪唑、2-氯丙烯取代生成1-甲基-3-烯丙基咪唑盐酸盐,再与尿素共熔制备得到。
4.根据权利要求3所述的一种解酒护肝的茶黄素组合物的制备方法,其特征在于,低共熔溶剂的制备方法包括以下步骤:
步骤A1、将N-甲基咪唑加入2-氯丙烯中,机械搅拌均匀,N2的保护下,升温至55-65℃,搅拌反应6-8h,反应结束后,与无水***混合,搅拌均匀,静置2-4h,分液,再将离子液体进行旋转蒸发,在80℃真空干燥48h,得到1-甲基-3-烯丙基咪唑盐酸盐;
步骤A2、将1-甲基-3-烯丙基咪唑盐酸盐和尿素加入三口烧瓶中,氮气保护下,升温至90℃,搅拌反应2-3h,得到低共熔溶剂。
5.根据权利要求4所述的一种解酒护肝的茶黄素组合物的制备方法,其特征在于,步骤A1中,N-甲基咪唑、2-氯丙烯和无水***的用量比为20-26mL:24-30mL;10-20mL。
6.根据权利要求4所述的一种解酒护肝的茶黄素组合物的制备方法,其特征在于,步骤A2中,1-甲基-3-烯丙基咪唑盐酸盐和尿素的用量比为15-25g:7.5-12.5g。
7.根据权利要求3所述的一种解酒护肝的茶黄素组合物的制备方法,其特征在于,常规辅料为药学上可接受的辅料。
8.根据权利要求3所述的一种解酒护肝的茶黄素组合物的制备方法,解酒护肝的茶黄素组合物被制备为口服制剂,口服制剂为汤剂、片剂、胶囊剂、散剂和颗粒剂的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310859488.2A CN116570703A (zh) | 2023-07-13 | 2023-07-13 | 一种解酒护肝的茶黄素组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310859488.2A CN116570703A (zh) | 2023-07-13 | 2023-07-13 | 一种解酒护肝的茶黄素组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116570703A true CN116570703A (zh) | 2023-08-11 |
Family
ID=87543541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310859488.2A Pending CN116570703A (zh) | 2023-07-13 | 2023-07-13 | 一种解酒护肝的茶黄素组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116570703A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1061436A (zh) * | 1991-10-31 | 1992-05-27 | 山西中医学院 | 一种解酒醋的制备方法 |
CN103285252A (zh) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | 一种解酒护肝口服液及其制备方法 |
CN106620357A (zh) * | 2017-02-17 | 2017-05-10 | 福建康是美生物科技有限公司 | 一种含茶多酚的解酒护肝中药组合物 |
CN107050189A (zh) * | 2017-05-09 | 2017-08-18 | 冯海强 | 一种黑枸杞加药食同源中药伴侣制品以及制备方法 |
CN109939201A (zh) * | 2019-01-04 | 2019-06-28 | 康赋葆(深圳)生物医药科技有限公司 | 解酒护肝的组合物及其制备方法和应用 |
-
2023
- 2023-07-13 CN CN202310859488.2A patent/CN116570703A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1061436A (zh) * | 1991-10-31 | 1992-05-27 | 山西中医学院 | 一种解酒醋的制备方法 |
CN103285252A (zh) * | 2012-12-27 | 2013-09-11 | 福建永生活力生物工程有限公司 | 一种解酒护肝口服液及其制备方法 |
CN106620357A (zh) * | 2017-02-17 | 2017-05-10 | 福建康是美生物科技有限公司 | 一种含茶多酚的解酒护肝中药组合物 |
CN107050189A (zh) * | 2017-05-09 | 2017-08-18 | 冯海强 | 一种黑枸杞加药食同源中药伴侣制品以及制备方法 |
CN109939201A (zh) * | 2019-01-04 | 2019-06-28 | 康赋葆(深圳)生物医药科技有限公司 | 解酒护肝的组合物及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
冯靖等: "离子液体在提取天然产物活性物质中的应用", 应用化工, vol. 48, no. 4, pages 945 - 949 * |
李昌文等: "核桃多肽制备技术及生理活性研究进展", 食品工业, vol. 41, no. 09, pages 257 - 259 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101011561B (zh) | 黄连温胆汤现代中药口服制剂及其生产方法 | |
CN103861060B (zh) | 一种解酒片及其制备方法 | |
CN102836379B (zh) | 一种降脂解酒的中药复方制剂及其制备方法与应用 | |
CN102258708A (zh) | 一种养生酒及其制备方法 | |
CN108391774A (zh) | 一种抗痛风的功能饮料及其制备方法 | |
CN107518133A (zh) | 一种解酒护肝花茶及其制备方法 | |
CN107873915A (zh) | 一种枸杞姜枣茶及其制备方法 | |
CN104383315A (zh) | 一种护肝醒酒的中草药组合物及含有该组合物的饮品 | |
CN104904964A (zh) | 一种降糖降脂的罗布麻叶保健茶及其制备方法 | |
CN104873808A (zh) | 一种降三高的保健茶 | |
CN113456725A (zh) | 一种解酒产品及其制备方法 | |
CN104946488B (zh) | 养生龟酒及其制备方法 | |
CN105878812A (zh) | 以金花茶-石斛为原料的解酒饮料及其生产方法 | |
CN105687788A (zh) | 一种软化血管的药物组合物及其应用 | |
CN103181431B (zh) | 一种养肝保健茶及其制备方法 | |
CN105077501A (zh) | 一种青年女性用减肥饮料 | |
CN116570703A (zh) | 一种解酒护肝的茶黄素组合物及其制备方法 | |
CN114767826A (zh) | 一种醒酒护肝组合物、具有醒酒护肝功效的饮料及其制备方法 | |
CN111658746B (zh) | 一种用于治疗酒精性脂肪肝的中药组合物及其制备方法 | |
CN104026295B (zh) | 一种降血压血糖保健茶 | |
CN105833172A (zh) | 用于治疗无症状性心肌缺血的中药冲剂及制备方法 | |
CN101433577A (zh) | 一种绿豆解酒剂及其制备方法 | |
CN100574799C (zh) | 人参四逆注射剂及制备方法 | |
CN109717437A (zh) | 一种解酒复合蜂蜜膏及其制备方法 | |
CN109876053A (zh) | 一种祛痘消炎、清肝解毒的组方及其制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230811 |